Trinity Biotech plc announced operational progress including the appointment of Jordi Romero as Head of Commercial Operations – Europe and the rollout of upgraded HbA1c column technology in three major markets. The company completed manufacturing approximately 9 million TrinScreen HIV tests under a new outsourced model and commenced production of Uni-Gold™ HIV, expecting margin improvements upon full scale-up. Additionally, the PrePsia™ patent portfolio expanded to nine granted patents in the U.S. and Europe. However, the filing disclosed that Trinity Biotech failed to regain compliance with Nasdaq’s $15 million market value of publicly held shares requirement by the August 18, 2026 deadline. Consequently, the company intends to request a hearing before a Hearings Panel to seek an extension until February 24, 2027, to avoid suspension or delisting from the Nasdaq Global Select Market. Trinity Biotech operates in the human diagnostics and diabetes management solutions industry.
